Nature Communications (May 2019)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
- Patrick A. Baeuerle,
- Jian Ding,
- Ekta Patel,
- Niko Thorausch,
- Holly Horton,
- Jessica Gierut,
- Irene Scarfo,
- Rashmi Choudhary,
- Olga Kiner,
- Janani Krishnamurthy,
- Bonnie Le,
- Anna Morath,
- G. Christian Baldeviano,
- Justin Quinn,
- Patrick Tavares,
- Qi Wei,
- Solly Weiler,
- Marcela V. Maus,
- Daniel Getts,
- Wolfgang W. Schamel,
- Robert Hofmeister
Affiliations
- Patrick A. Baeuerle
- TCR² Therapeutics, Inc.
- Jian Ding
- TCR² Therapeutics, Inc.
- Ekta Patel
- TCR² Therapeutics, Inc.
- Niko Thorausch
- Department of Immunology, Faculty of Biology, BIOSS Center for Biological Signalling Studies, CIBSS—Centre for Integrative Biological Signalling Studies and Centre for Chronic Immunodeficiency CCI, University of Freiburg
- Holly Horton
- TCR² Therapeutics, Inc.
- Jessica Gierut
- TCR² Therapeutics, Inc.
- Irene Scarfo
- Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School
- Rashmi Choudhary
- TCR² Therapeutics, Inc.
- Olga Kiner
- TCR² Therapeutics, Inc.
- Janani Krishnamurthy
- TCR² Therapeutics, Inc.
- Bonnie Le
- TCR² Therapeutics, Inc.
- Anna Morath
- Department of Immunology, Faculty of Biology, BIOSS Center for Biological Signalling Studies, CIBSS—Centre for Integrative Biological Signalling Studies and Centre for Chronic Immunodeficiency CCI, University of Freiburg
- G. Christian Baldeviano
- TCR² Therapeutics, Inc.
- Justin Quinn
- TCR² Therapeutics, Inc.
- Patrick Tavares
- TCR² Therapeutics, Inc.
- Qi Wei
- TCR² Therapeutics, Inc.
- Solly Weiler
- TCR² Therapeutics, Inc.
- Marcela V. Maus
- Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School
- Daniel Getts
- TCR² Therapeutics, Inc.
- Wolfgang W. Schamel
- Department of Immunology, Faculty of Biology, BIOSS Center for Biological Signalling Studies, CIBSS—Centre for Integrative Biological Signalling Studies and Centre for Chronic Immunodeficiency CCI, University of Freiburg
- Robert Hofmeister
- TCR² Therapeutics, Inc.
- DOI
- https://doi.org/10.1038/s41467-019-10097-0
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
Supraphysiological T cell activation by chimeric antigen receptor (CAR) contributes to T cell exhaustion and adverse events in CAR T cell therapies. Here the authors engineer a synthetic antigen receptor that integrates into the endogenous TCR complex, preserving natural regulatory circuits and achieving improved performance in mouse tumor models.
